FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer.
The MOSAIC trial showed that the use of adjuvant oxaliplatin and an infusional regimen of 5-FU/LV in the treatment of stage II/III colon cancer improved disease-free survival (DFS). The NSABP's C-07 trial evaluated the addition of oxaliplatin to a weekly Roswell Park regimen of bolus 5-FU/LV and found a similar improvement in DFS. The benefit of oxaliplatin appears to be independent of the 5-FU/LV regimen used. This paper reviews the efficacy and toxicities of these two regimens and is meant to serve as a guide for clinical practice.
Sharif
Saima
S
National Surgical Adjuvant Breast and Bowel Project Operations Office, Pittsburgh, Pennsylvania, USA. saima.sharif@nsabp.org
O'Connell
Michael J
MJ
Yothers
Greg
G
Lopa
Samia
S
Wolmark
Norman
N
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D000077150:Oxaliplatin; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil
J Clin Oncol. 2000 Aug;18(16):2938-47
10944126
J Clin Oncol. 1993 Oct;11(10):1879-87
8410113
J Clin Oncol. 2007 Jun 1;25(16):2205-11
17470850
J Clin Oncol. 2007 May 1;25(13):1658-64
17470858
N Engl J Med. 2004 Jun 3;350(23):2343-51
15175436
Cancer. 2007 Nov 1;110(9):1945-50
17853393
N Engl J Med. 2004 Jul 22;351(4):337-45
15269313
J Clin Oncol. 1997 Feb;15(2):808-15
9053508
J Clin Oncol. 2005 Dec 1;23(34):8664-70
16260700
Lancet. 2000 Mar 25;355(9209):1041-7
10744089
J Clin Oncol. 2004 Jan 1;22(1):23-30
14665611
N Engl J Med. 2004 Jun 3;350(23):2335-42
15175435
J Clin Oncol. 2007 Jun 1;25(16):2198-204
17470851
Adv Exp Med Biol. 1988;244:143-55
3073651